Citizens Maintains An Outperform Rating On Terns Pharmaceuticals, Inc. (TERN)

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is among the 20 Best Performing Stocks in 2025.

On December 11, 2025, TheFly reported that Citizens boosted its price goal for Terns Pharmaceuticals, Inc. (NASDAQ:TERN) to $57 from $35. The firm retained an Outperform rating, noting interim Phase 1 CARDINAL ASH data confirming a best-in-class profile for TERN-701. The firm identified strong activity after asciminib and ponatinib, which it considers favorable for second-line use, and a high deep molecular response rate that supports first-line potential.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) released third-quarter 2025 results and corporate updates, pointing out that an ASH 2025 abstract featured unprecedented Phase 1 CML efficacy data and a possible best-in-disease profile for TERN-701. An expanded and updated CARDINAL dataset is anticipated to be included in an upcoming ASH oral presentation.

Separately, the firm reported $295.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, down from $358.2 million as of December 31, 2024. The company stated that current funds are anticipated to cover planned operating costs until 2028.

Nonetheless, the stock is down by 3.07% as of January 6, 2026.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical business.

While we acknowledge the potential of TERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None